Background. Nitric oxide (NO), a key macrophage antimycobacterial mediator that ameliorates immunopathology, is measurable in exhaled breath in individuals with pulmonary tuberculosis. We investigated relationships between fractional exhale NO (FENO) and initial pulmonary tuberculosis severity, change during treatment, and relationship with conversion of sputum culture to negative at 2 months. Methods. In Papua, we measured FENO in patients with pulmonary tuberculosis at baseline and serially over 6 months and once in healthy controls. Treatment outcomes were conversion of sputum culture results at 2 months and time to conversion of sputum microscopy results. Results. Among 200 patients with pulmonary tuberculosis and 88 controls, FENO was lower for patients with pulmonary tuberculosis at diagnosis (geometric mean FENO, 12.7 parts per billion [ppb]; 95% confidence interval [CI], 11.6-13.8) than for controls (geometric mean FENO, 16.6 ppb; 95% CI, 14.2-19.5; P =. 002), fell further after treatment initiation (nadir at 1 week), and then recovered by 6 months (P =. 03). Lower FENO was associated with more-severe tuberculosis disease, with FENO directly proportional to weight (P
CITATION STYLE
Ralph, A. P., Yeo, T. W., Salome, C. M., Waramori, G., Pontororing, G. J., Kenangalem, E., … Anstey, N. M. (2013). Impaired pulmonary nitric oxide bioavailability in pulmonary tuberculosis: Association with disease severity and delayed mycobacterial clearance with treatment. Journal of Infectious Diseases, 208(4), 616–626. https://doi.org/10.1093/infdis/jit248
Mendeley helps you to discover research relevant for your work.